Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,766.40
(
-1.52%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.29
(
6.60%
)
Bitcoin
71,265.40
(
-3.62%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 91506

Tuesday, 03/02/2010 7:59:29 PM

Tuesday, March 02, 2010 7:59:29 PM

Post# of 257257
LOL—true! I haven’t been listing IDIX’s NS5A inhibitor in the “HCV: Most Likely to Succeed” compilation because it doesn’t yet have a code name; however, I’ve been listing several other preclinical compounds that don’t yet have a name. In other words, I’ve been applying a double standard that penalized IDIX. This double standard will now end!


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now